“The need for vaccines against COVID-19 is enormous. We are therefore pleased to be able to provide significant support to CureVac, a leader in mRNA technology, in advancing the further development and supply of its COVID-19 vaccine candidate,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of the Bayer’s Pharmaceuticals Division. “We are highly committed to making our capabilities and networks available to help end this pandemic.”
“We are very happy to join forces with Bayer, whose expertise and infrastructure will help us make our vaccine candidate CVnCoV even more rapidly available to as many people as possible,” said Dr. Franz-Werner Haas, Chief Executive Officer of CureVac. “Building on the positive data we have seen so far with CVnCoV, we now also have another strong partner on our side to get the vaccine to the people who need it following the receipt of the requisite regulatory approvals.”
Based on the collaboration agreement, CureVac will be the Marketing Authorization Holder for the product, while Bayer will support CureVac with country operations within the European Union (EU) and selected additional markets. Bayer holds further options to become Marketing Authorization Holder in other markets outside of Europe. The companies plan to combine their strengths for CureVac to be in a position to supply hundreds of millions of CVnCoV doses around the world, once approvals are granted. Together both companies aim to play a meaningful role to contribute to stop the COVID-19 pandemic.CureVac is currently expanding its partner network for the development, production and distribution of its vaccine candidate. In November 2020, the company announced that it would ramp up its European manufacturing network, working with Wacker and Fareva, amongst others. On December 14, 2020 the company achieved another milestone in the development of CVnCoV with the start of its global pivotal Phase 2b/3.